The Rheumatology Drugs for COVID-19 Management: Which and When?
Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-α, which hallmarks the most severe clinical cases. ‘Repurposing’ immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 10(2021), 4, p 783 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fabiola Atzeni [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.3390/jcm10040783 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ014837153 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ014837153 | ||
| 003 | DE-627 | ||
| 005 | 20240414031611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm10040783 |2 doi | |
| 035 | |a (DE-627)DOAJ014837153 | ||
| 035 | |a (DE-599)DOAJeed9aecee95846eb8a00f107e4a1a0b4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Fabiola Atzeni |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Rheumatology Drugs for COVID-19 Management: Which and When? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-α, which hallmarks the most severe clinical cases. ‘Repurposing’ immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients. | ||
| 650 | 4 | |a pneumonia | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 4 | |a anti-IL-6 drugs | |
| 650 | 4 | |a HCQ | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Ignazio Francesco Masala |e verfasserin |4 aut | |
| 700 | 0 | |a Javier Rodríguez-Carrio |e verfasserin |4 aut | |
| 700 | 0 | |a Roberto Ríos-Garcés |e verfasserin |4 aut | |
| 700 | 0 | |a Elisabetta Gerratana |e verfasserin |4 aut | |
| 700 | 0 | |a Laura La Corte |e verfasserin |4 aut | |
| 700 | 0 | |a Manuela Giallanza |e verfasserin |4 aut | |
| 700 | 0 | |a Valeria Nucera |e verfasserin |4 aut | |
| 700 | 0 | |a Agostino Riva |e verfasserin |4 aut | |
| 700 | 0 | |a Gerard Espinosa |e verfasserin |4 aut | |
| 700 | 0 | |a Ricard Cervera |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 10(2021), 4, p 783 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:4, p 783 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm10040783 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/eed9aecee95846eb8a00f107e4a1a0b4 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/10/4/783 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 4, p 783 | ||